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PIntravascular Imaging and Vulnerable Plaque
olumetric Quantitative Analysis of
issue Characteristics of Coronary Plaques
fter Statin Therapy Using Three-Dimensional
ntegrated Backscatter Intravascular Ultrasound
asanori Kawasaki, MD, PHD,* Keiji Sano, MD, PHD,* Munenori Okubo, MD,* Haruko Yokoyama, MD,*
oko Ito, MD, PHD,* Ichijiro Murata, MD, PHD,* Kunihiko Tsuchiya, MD, PHD,*
hinya Minatoguchi, MD, PHD,* Xiangrong Zhou, PHD,† Hiroshi Fujita, PHD,†
isayoshi Fujiwara, MD, PHD*
ifu, Japan
OBJECTIVES The purpose of the present study was twofold: 1) to evaluate the usefulness of three-
dimensional (3D) integrated backscatter (IB) intravascular ultrasound (IVUS) for quantitative
tissue characterization of coronary plaques; and 2) to use this imaging technique to determine
if six months of statin therapy alters the tissue characteristics of coronary plaques.
BACKGROUND Three-dimensional IVUS techniques for quantitative tissue characterization of plaque
composition have not been developed.
METHODS Radiofrequency (RF) signals were obtained using an IVUS system with a 40-MHz catheter.
The IB values of the RF signal were calculated and color-coded. The 3D reconstruction of
the color-coded map was performed by computer software. A total of 18 IB IVUS images
were captured at an interval of 1 mm in each plaque. A total of 52 patients with
hyperlipidemia were randomized to treatment with pravastatin (20 mg/day, n  17),
atorvastatin (20 mg/day, n  18), or diet (n  17) for six months. The tissue characteristics
of arterial plaque in each patient (one arterial segment per patient) were analyzed with 3D IB
IVUS before and after treatment.
RESULTS Significant increases of fibrous volume (pravastatin: 25.4 6.5% to 28.1 6.1%; atorvastatin:
26.2  5.7% to 30.1  5.5%) and mixed lesion volume (atorvastatin: 25.5  6.6% to 28.7 
5.1%) and a reduction of lipid volume (pravastatin: 25.5 5.7% to 21.9 5.3%; atorvastatin:
26.5  5.2% to 19.9  5.5%) were observed after statin therapy.
CONCLUSIONS Statin therapy reduced the lipid component in patients with stable angina without reducing
the degree of stenosis. Three-dimensional IB IVUS offers the potential for quantitative
volumetric tissue characterization of coronary atherosclerosis. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.0811946–53) © 2005 by the American College of Cardiology Foundation
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fintravascular ultrasound (IVUS) allows tomographic imag-
ng of coronary arteries and provides a more comprehensive
ssessment of the atherosclerotic plaques in vivo than the
luminal silhouette” furnished by coronary angiography.
See page 1970
urthermore, three-dimensional (3D) image reconstruction
echniques have been developed to perform volumetric
nalyses (1–3). Electrocardiographic (ECG)-gated acquisi-
ion of 3D IVUS image sets is feasible and permits the
pplication of automated contour detection to provide
eproducible measurements of the lumen and atherosclerotic
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nd Technology of Japan.c
Manuscript received May 24, 2004; revised manuscript received August 14, 2004,
ccepted September 17, 2004.laque cross-sectional area and volume in a relatively short
nalysis time (4,5).
Previously, many techniques for the tissue characteriza-
ion of plaque composition have been developed using
wo-dimensional (2D) IVUS (6–8). Recently, it has been
eported that autoregressive classification techniques allow
he analysis of IVUS data, enabling in vivo plaque charac-
erization (9). Also, we developed an integrated backscatter
IB) IVUS system in which 2D color-coded maps for tissue
haracterization of coronary plaques were constructed by
omputer (10). This method is based on the analysis by IB
ignals. We reported on the tissue characterization of
rterial plaques in human carotid and coronary arteries in
ivo using IB ultrasound (10,11). These studies showed IB
easurements accurately reflected the tissue characteristics
f human carotid arterial plaques, and IB values recorded in
ivo were precisely correlated with either the IB values
btained just after excision at autopsy or the IB values after
xation (11). Moreover, it was reported that IB values of
arotid arteries reflected the risk of atherosclerosis in pa-
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June 21, 2005:1946–53 Volumetric Analysis of Plaques After Statin Therapyients with ischemic heart disease (12). However, 3D IVUS
echniques for tissue characterization of plaque composition
ave not been developed.
Substantial reduction of acute cardiac events has been
hown in most of the lipid-lowering trials, despite only a
inimal geometric regression of plaque (13–16). The pre-
ention of acute coronary syndrome with 3-hydroxy-3-
ethylglutaryl coenzyme A reductase inhibitors (statins) is
ssociated with stabilization of coronary plaques but no
mprovement of the degree of stenosis (17,18). Statin-
nduced plaque stabilization is thought to be due to a change
n plaque composition from a large lipid core with a thin
brous cap into a small lipid core with a thick fibrous cap
17). Although animal studies support this hypothesis, there
re little data on the tissue characteristics of coronary
laques in patients before and after statin therapy (19).
The purpose of the present study was two-fold: 1) to
valuate the usefulness of 3D IB IVUS for quantitative
issue characterization or coronary plaques; and 2) to use
his imaging technique to determine if six months of statin
herapy alters the tissue characteristics of coronary plaques.
ETHODS
atients and study design. This study was a simple ran-
omization, open-label, single-center study of patients with
yperlipidemia. The study included 52 patients stable an-
ina pectoris not currently on statin therapy, but with total
holesterol concentrations above 220 mg/dl at the time of
nrollment. Patients with unstable angina or myocardial
nfarction within the previous four weeks, ejection fraction
30%, secondary causes of hypercholesterolemia, and se-
ere hypertriglyceridemia (400 mg/dl) were excluded.
atients were randomized to one of three groups: pravasta-
in (20 mg/day, n  19), atorvastatin (20 mg/day, n  20),
nd control (n  18). The control group was treated with
ietary stabilization only. Study patients were referred to a
utritionist for individual counseling and were also provided
ith a lifestyle-changing program that included cessation of
moking. Informed consent was obtained from patients and
heir relatives before randomization in all cases. The pa-
ients in the control group were given the option of statin
herapy if the lipid volume of their coronary plaques
Abbreviations and Acronyms
2D  two-dimensional
3D  three-dimensional
DM  diabetes mellitus
ECG  electrocardiogram/electrocardiographic
HL  hyperlipidemia
HTN  hypertension
IB  integrated backscatter
IVUS  intravascular ultrasound
RF  radiofrequency
ROI  region of interestncreased after six months. Two patients in the pravastatin
vroup and two patients in the atorvastatin group did not
omplete the study because of interruption of treatment.
ne patient in the control group did not complete the study
ecause of relocation. There were no serious cardiovascular
vents, such as myocardial infarction, unstable angina, or
eath, in any group. At baseline and after six months, all
atients had intracoronary interventions and IB IVUS
nalyses performed in coronary arteries with mild or mod-
rate stenosis. The plaques analyzed in this study had to be
ore than 20 mm from the intervention site. Another
oronary artery was analyzed if there was no plaque with
ild or moderate stenosis in the vessel that was the target of
he intervention. Coronary arteries were excluded if an
VUS catheter could not be inserted because of severe
tenosis. Risk factors for coronary artery disease were
valuated in each patient, including diabetes mellitus
medication-dependent, including oral hypoglycemic drugs
nd insulin), hypertension (medication-dependent only),
nd smoking status (current smoker or quit 6 months
efore the study).
B system presets and data acquisition. An analog-digital
onverter (Wavepro 960, LeCroy, Chestnut Ridge, New
ork) and ECG monitor were connected, and a trigger was
et in coordinate with the ECG. The radiofrequency (RF)
ignals were acquired at the top of the R-wave of the ECG
fter detection of a regular R-R interval at one site. Then,
he catheter was pulled back at 1-mm interval by activating
he pull-back motor. Conventional IVUS images and IB
ignals were acquired at end diastole using an IVUS imaging
ystem (Clear View, Boston Scientific, Natick, Massachu-
etts) and a 40-MHz intravascular catheter. For the preven-
ion of coronary spasm, we administered an intracoronary
ptimal dose of isosorbide dinitrate before the measure-
ents. A target coronary segment was selected by the
resence of an easily definable branch to ensure a reliable
omparison between baseline and six-month follow-up. A
otal of 18 IB IVUS images were captured at an interval of
mm using a motorized pull-back system in each plaque.
e used an analog-digital converter, which enabled acqui-
ition, storage, and retrieval of signals that were digitized at
GHz with 8-bit resolution. Off-line calculation of IB
alues of the acquired RF signals was performed by retriev-
ng the previously stored data from the built-in memory
Compact Flash, San Disk, Sunnyvale, California), using
oftware we developed for this study. Our definition of IB
able 1. Definition of IB Values in Each of Histological
ategories in Plaque
Histology
IB Values (dB)
Mean  SD Definition (dB)
alcification 26.7  3.6 30  IB  23
ixed lesion 40.7  4.6 55  IB  30
ibrosis 58.9  3.6 63  IB  55
ipid pool 67.5  3.6 73  IB  63
ur definition of IB values in each histological category was based on the mean IB
alues  1 SD reported in our previous study (10).
IB  integrated backscatter.
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Volumetric Analysis of Plaques After Statin Therapy June 21, 2005:1946–53alues for each histologic category was determined by
omparing the histologic images reported in our previous
tudy (Table 1) (10). In the present study, we used 256
ector lines per image (1.4 grade/line) and set 20 regions of
nterest (ROIs) for each 100 m depth on each vector line
total 5,120 ROIs/image).
onstruction of 3D color-coded maps using IB values. In
he polar coordinates we used in the 2D color-coded maps,
he size of each ROI was different. To make the volumetric
nalysis more accurate in the present study, polar coordi-
ates were transformed into cartesian coordinates (64  64
ixels) using computer software. We then manually ex-
luded the vessel lumen and area outside of the intima in the
D IB IVUS images. Three-dimensional construction and
alculation of the number of voxels of each tissue charac-
eristic were automatically performed by commercially avail-
ble computer software (T3D, Fortner Research LLC,
terling, Virginia). The software connected 18 consecutive
mages.
onventional IVUS and IB IVUS parameters. Each
onventional IVUS and IB IVUS parameter was measured
t baseline and after six months in each group. After
oronary angiography, IVUS studies were performed by an
xperienced investigator blinded to the treatment. Cross-
ectional lumen area, cross-sectional vessel area within the
xternal elastic membrane, and plaque area (external elastic
embrane area minus lumen area) were determined by use
f the software attached to the IVUS system. Conventional
D IVUS image analysis was performed using an automated
D IVUS image analysis system (NetraIVUS, ScImage, Los
ltos, California) consisting of a semiautomatic user-guided
oundary delineation tool for segmentation of structures of
nterest. The system, which has been applied successfully to
he volumetric analysis in computed tomography and mag-
etic resonance imaging, utilizes a shape-based interpola-
ion algorithm.igure 1. (A) The three-dimensional (3D) color-coded maps of the coronary
ltrasound. (B) The 3D color-coded maps of each characteristic. The numberThe IVUS determinations were based on the observance
f two specialists who were blinded to the patients’ charac-
eristics. High-signal lesion (the part of the calcification on
he inner surface that could be measured), volume (number
f voxels of high-signal lesion/total number of plaque
oxels), fibrous volume (number of voxels of fibrosis/total
umber of plaque voxels), lipid volume (number of voxels of
ipid pool/total number of plaque voxels), and mixed lesion
olume (number of voxels of mixed lesion/total number of
laque voxels) were automatically measured in each plaque
sing T3D software (Fig. 1).
tatistical analyses. Laboratory and ultrasound parameters
ere reported as the mean value SD. Whether or not data
ere normally distributed was examined by the Kolmogrov-
mirnov test. If data were not normally distributed, testing
or significant differences of each parameter between base-
ine and six months was performed with the Mann-
hitney U test. If the data were normally distributed, but
he variances were significantly different when comparing
aseline versus six months, Welch’s t test was used. Other-
ise, the paired Student t test was used. Whether variances
ere significantly different was examined by the F test. The
ignificance of the differences among those parameters in
he three study groups was tested using one-way analysis of
ariance followed by Scheffe’s method of multiple compar-
sons, which was used for the post-hoc comparisons be-
ween groups. A p value 0.05 was considered to be
tatistically significant.
ESULTS
eproducibility of data. We determined intraobserver and
nterobserver variabilities of fibrous volume, lipid volume,
ixed lesion volume, and high-signal lesion volume in 20
andomly selected recordings that were measured twice by
he same observer and once each by two independentarterial plaques constructed by 3D integrated backscatter intravascular
of voxels of each tissue characteristic was automatically calculated.
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June 21, 2005:1946–53 Volumetric Analysis of Plaques After Statin Therapybservers. Intraobserver variabilities of each relative volume
ere 2.6  2.1%, 3.6  2.4%, 3.4  2.5%, and 1.9  1.1%,
espectively. Interobserver variabilities of each relative vol-
me were 2.1  2.3%, 3.6  2.4%, 2.6  2.1%, and 1.3 
.9%, respectively. Intraobserver correlations of each relative
olume were r  0.95 (p  0.01), r  0.92 (p  0.01), r 
.91 (p  0.01), and r  0.97 (p  0.01), respectively.
nterobserver correlations of each relative volume were r 
.96 (p  0.01), r  0.94 (p  0.01), r  0.95 (p  0.01),
nd r  0.97 (p  0.01), respectively.
onstruction of 3D color-coded map. The 3D IB IVUS
mages consisted of a total of 8,989  1,432 voxels in each
laque. The 3D IB IVUS images presented here can
isualize lipid pools, fibrous lesions, mixed lesions, and
igh-signal lesions (the part of the calcification on the inner
urface that could be measured) in the plaque of human
oronary arteries in vivo (Fig. 1). By looking at these images,
e were able to know the location of lipid pools, fibrous
esions, mixed lesions, and high-signal lesions in the plaque.
Table 2. Baseline Characteristics of the Patien
Variable Ator
Gender, n (%)
Men
Women
Age, yrs 66
Body mass index (kg/m2) 23.5
Clinical history, n (%)
Myocardial infarction 1
Hypertension 8
Diabetes mellitus type 2 4
Current smoker 4
Prior statin use 2
Number of coronary artery disease, n (%)
Single vessel 5
Multiple vessel 12
Target plaque location, n (%)
LAD 7
LCX 5
RCA 5
Medication, n (%)
Aspirin 17
Ticlopidine 17
Nitrates 12
Calcium channel blockers 11
Beta-blockers 3
Insulin 2
ACE inhibitors 9
AT1 antagonists 5
ACE  angiotensin-converting enzyme; LAD  left anterio
 right coronary artery.
able 3. Three-Dimensional Integrated Backscatter Intravascular
aseline Risk Factors
Parameter
HL
(n  21)
H
ibrous volume (%) 23.9  7.1
ipid volume (%) 25.5  5.1
ixed lesion volume (%) 27.0  6.3
igh signal lesion volume (%) 2.0  0.5alues are mean  SD. *p  0.05 vs. % high signal lesion volume in HL using analysis o
DM  diabetes mellitus; HL  hyperlipidemia; HTN  hypertension.issue characterization of each 3D IB IVUS image was
erformed by analyzing all voxels in each plaque.
ifferent tissue characteristics of plaques at baseline. There
ere no significant differences in the distribution of patients
ith coronary risk factors among the three groups (Table 2).
owever, there were significant differences in high-signal
esion volume among the patients with hyperlipidemia
HL), HL plus hypertension (HTN), HL plus diabetes
ellitus (DM), and HL plus HTN plus DM at baseline,
lthough there were no significant differences in the fibrous,
ipid, and mixed lesion volumes among these patients
Table 3).
aboratory profiles. There were no significant differences
ith regard to baseline characteristics and blood lipid
arameters at baseline among the three groups (Tables 2
nd 4). Total cholesterol significantly decreased in the
ravastatin and atorvastatin groups. After six months of
tatin therapy, the mean reduction in total cholesterol was
2% in the pravastatin group and 29% in the atorvastatin
in Pravastatin Control p Value
13 14 NS
5 3 NS
7 67  7.8 66  6.4 NS
3 24.1  3.0 23.1  3.5 NS
0 (0) 1 (6) NS
9 (50) 7 (41) NS
5 (28) 3 (18) NS
5 (28) 3 (18) NS
2 (11) 1 (6) NS
4 (22) 6 (35) NS
14 (78) 11 (65) NS
7 (39) 6 (35) NS
7 (39) 5 (29) NS
4 (22) 6 (35) NS
18 (100) 17 (100) NS
18 (100) 17 (100) NS
15 (83) 12 (71) NS
13 (72) 10 (56) NS
4 (22) 3 (18) NS
2 (11) 3 (18) NS
10 (56) 7 (41) NS
4 (22) 6 (35) NS
ending coronary artery; LCX  left circumflex artery; RCA
asound Parameters of Patients Stratified by
HTN
19)
HL  DM
(n  7)
HL  HTN  DM
(n  5)
 5.9 23.9  4.2 29.3  4.0
 5.5 26.2  7.0 27.5  3.1
 6.0 26.7  7.4 27.0  4.7
 0.5* 2.7  0.4* 2.9  0.4*ts
vastat
12
5
 8.
 3.
(6)
(47)
(24)
(24)
(12)
(29)
(71)
(41)
(29)
(29)
(100)
(100)
(71)
(65)
(18)
(12)
(53)
(29)Ultr
L 
(n 
27.0
25.5
26.7
2.5f variance.
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Volumetric Analysis of Plaques After Statin Therapy June 21, 2005:1946–53roup. The mean reductions in low-density lipoprotein
holesterol, triglycerides, and C-reactive protein were 32%,
1%, and 18% in the pravastatin group and 39%, 12%, and
5% in the atorvastatin group, respectively. High-density
ipoprotein cholesterol significantly increased in the atorva-
tatin group. However, there was no significant difference of
hose parameters between baseline and six-month follow-up
n the control group.
onventional IVUS and IB IVUS measurement. There
ere no significant differences among the three treatment
roups in vessel area, lumen area, plaque area, and stenosis
iameter or area at baseline. There were also no significant
ifferences between baseline and six months in the stenosis
iameter, stenosis area, and plaque volume in the three
reatment groups (Table 5). However, a significant increase
n fibrous volume and a reduction in lipid volume were
bserved, despite no significant differences in fibrous vol-
me or lipid volume in the control group. Mixed lesion
olume significantly increased only in the atorvastatin group
Table 6). Figure 2 illustrates changes in IB IVUS images of
plaque before and after statin therapy.
ISCUSSION
revious studies suggest that plaque rupture and acute
cclusion occur at the site of unstable plaques, where there
s a high lipid content covered by a thin fibrous cap (20,21).
he presence of lipid-rich plaque may be an important
rerequisite for plaque vulnerability (22). Conventional
chocardiographic techniques, especially IVUS imaging, are
idely used to determine calcification of the three layers of
he arterial vessel wall and the degree of plaque calcification.
owever, it is difficult to detect vulnerable plaques using
able 4. Changes in Laboratory Profiles
Parameter Baseline Month 6
Reduction
(%)
otal cholesterol (mg/dl)
Atorvastatin 244  21 174  22* 29
Pravastatin 250  22 196  23* 22
Control 241  27 240  46 0
DL cholesterol (mg/dl)
Atorvastatin 50  9 56  10* 12
Pravastatin 54  12 56  10 4
Control 50  10 51  11 2
DL cholesterol (mg/dl)
Atorvastatin 155  22 95  15* 39
Pravastatin 149  19 102  13* 32
Control 152  20 149  24 2
riglycerides (mg/dl)
Atorvastatin 146  27 129  26* 12
Pravastatin 155  26 139  28* 11
Control 155  29 160  32 3
-reactive protein (mg/dl)
Atorvastatin 0.38  0.47 0.13  0.17† 65
Pravastatin 0.33  0.16 0.27  0.19† 18
Control 0.30  0.31 0.35  0.43 17
alues are mean SD. *p 0.01, †p 0.05 between at baseline and after 6 months.
HDL  high-density lipoprotein; LDL  low-density lipoprotein.onventional IVUS. Detecting vulnerable plaques is one of Ihe most important endeavors in the field of cardiology.
ecently, mathematical analysis of RF signals from IVUS
nd color mapping of angle-dependent echo-intensity vari-
tion have been developed for detecting vulnerable plaques
6,7). In addition, IVUS elastography has been shown to
istinguish different plaque morphologies in vivo (9).
In this study, we describe a method of tissue character-
zation of coronary plaques using an IB IVUS imaging
ystem. The present system with the commercially available
VUS imaging system (Boston Scientific), digital-analog
onverter (Wavepro 960, LeCroy), and computer software
T3D, Fortner Research LLC) made tissue characterization
f coronary plaques possible without any reconstruction
rom video recorder images (10).
econstruction of 3D IB IVUS color-coded maps. Pre-
iously, several 3D reconstruction techniques of conven-
ional IVUS images have been established. Computer-aided
D reconstruction connecting cross-sectional IVUS images,
igitized every 0.2 mm using a motorized pull-back device,
llows the reproducible and reliable measurement of plaque
olume that reflects the morphologic features of the plaque
23). Volumetric measurements derived from IVUS images
re highly reproducible and useful for monitoring the progres-
able 5. Changes in Lesion Characteristics
Parameter Baseline Month 6
Reduction
(%)
p
Value
ngiographic stenosis
diameter (%)
Atorvastatin 40.9  5.2 40.3  5.0 1 NS
Pravastatin 41.3  6.7 41.6  7.1 0 NS
Control 38.3  5.3 39.5  5.5 3 NS
essel area (mm2)
Atorvastatin 12.8  2.2 13.2  2.4 3 NS
Pravastatin 13.4  1.9 13.2  2.1 1 NS
Control 12.5  2.2 12.8  2.1 2 NS
umen area (mm2)
Atorvastatin 4.4  0.8 4.8  1.2 9 NS
Pravastatin 4.8  0.9 4.7  1.2 2 NS
Control 5.0  0.9 4.9  1.1 2 NS
laque area (mm2)
Atorvastatin 8.4  2.2 8.3  2.3 0 NS
Pravastatin 8.9  2.1 8.7  2.4 2 NS
Control 7.5  2.1 8.0  2.4 7 NS
laque burden (%)
Atorvastatin 65.5  12.6 62.3  11.3 0 NS
Pravastatin 66.1  10.1 66.3  10.4 0 NS
Control 60.7  9.1 62.3  10.4 3 NS
essel volume (mm3)
Atorvastatin 232.6  39.6 230.6  43.2 1 NS
Pravastatin 239.2  34.2 237.6  37.8 1 NS
Control 230.1  39.6 231.4  37.8 1 NS
umen volume (mm3)
Atorvastatin 72.3  15.1 75.1  14.2 4 NS
Pravastatin 74.1  12.9 73.6  15.2 1 NS
Control 72.1  13.2 72.4  15.8 0 NS
laque volume (mm3)
Atorvastatin 159.2  31.6 155.4  32.8 2 NS
Pravastatin 166.2  29.5 164.6  34.5 1 NS
Control 159.0  30.2 159.0  29.5 0 NSVUS  intravascular ultrasound.
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June 21, 2005:1946–53 Volumetric Analysis of Plaques After Statin Therapyion and regression of atherosclerotic plaque volume in a
ongitudinal study (24). The acoustic characterization of the
omposition of a coronary plaque by use of conventional IVUS
as been validated by in vitro and in vivo studies (25,26).
igure 2. Color-coded maps of the coronary arterial plaques constructed by
t baseline and after statin therapy. (A) At baseline, the plaque consisted of
tatin therapies, the lipid core (blue) decreased and the fibrous area (green
able 6. Changes in Three-Dimensional Integrated Backscatter
ntravascular Ultrasound Parameters
Parameter Baseline Month 6
Reduction
(%)
ibrous volume (%)
Atorvastatin 26.2  5.7 30.1  5.5* 15
Pravastatin 25.4  6.5 28.1  6.1† 11
Control 24.6  6.8 25.6  6.3 4
ipid volume (%)
Atorvastatin 26.5  5.2 19.9  5.5*‡ 25
Pravastatin 25.5  5.7 21.9  5.3† 14
Control 25.5  5.7 26.9  4.2 5
ixed lesion volume (%)
Atorvastatin 25.5  6.6 28.7  5.1* 13
Pravastatin 27.5  5.8 29.8  5.8 8
Control 27.6  4.1 28.1  5.2 2
igh signal lesion
volume (%)
Atorvastatin 2.3  0.6 2.4  0.6 4
Pravastatin 2.2  0.6 2.4  0.7 9
Control 2.4  0.6 2.5  0.6 4
alues are mean  SD. *p  0.01, †p  0.05 between baseline and 6 months. ‡p 
.01 vs. control using a one-way analysis of variance.small lipid core (blue) in the center of the plaque. (D) Cut-out image of 3D c
ed  high signal lesion; yellow  mixed lesion.owever, 3D reconstruction of conventional IVUS images
howed a good reflection of morphologic features but not
istologic features of the plaques. The 3D IB IVUS color-
oded maps consecutively connecting 18 images digitized every
mm offer the potential to characterize coronary plaques
nd count the ratio of each tissue characteristic (Fig. 1).
laque stabilization after statin therapy. There are some
ata obtained by a few maneuvers that indicate plaque
tability after statin therapies. Recently, angioscopy has
hown that atorvastatin treatment (10 to 30 mg/day) for one
ear changed plaque color and morphology and led to
oronary plaque stabilization (27). In that study, the mean
ellow score significantly decreased after statin therapy. The
esults of the present study are compatible with that study
ecause our previous work showed that the surface color of the
laque evaluated with angioscopy reflects the thickness of the
brous cap determined with 2D IB IVUS imaging (10).
Previous analysis of plaque stability using conventional
VUS showed that atorvastatin treatment for one year in the
erman Atorvastatin Intravascular Ultrasound (GAIN)
tudy was associated with an increased hyperechogenic
laque area, which in turn was associated with a larger
raction of dense fibrous and elastic tissue without plaque
olume regression (28). In that study, there was no signif-
cant difference in hypoechogenic plaque area between
-dimensional (3D) integrated backscatter intravascular ultrasound imaging
ge lipid core (blue), which is covered with a fibrous cap (green). (B) After
eased. (C) Cut-out image of 3D color-coded map at baseline. There wasthree
a lar
) incrolor-coded map after statin therapy. Note the reduction in the lipid core.
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Volumetric Analysis of Plaques After Statin Therapy June 21, 2005:1946–53aseline and one year, because the detection of the lipid core
y use of conventional IVUS was not quantitative. In the
resent quantitative study, the relative fibrous volume sig-
ificantly increased and the relative lipid volume signifi-
antly decreased after therapy with both atorvastatin and
ravastatin, without improvement in the degree of stenosis.
With respect to the relationship between the regression of
he plaque area and the follow-up period, it was reported
hat progression and regression did not occur after 1.5 years
f statin therapy (atorvastatin 80 mg/day) in the Reversal of
therosclerosis with Aggressive Lipid Lowering (REVER-
AL) study (18). In addition, in the GAIN study, regres-
ion of the plaque area did not occur after one year of statin
herapy (atorvastatin 20 to 40 mg/day) (28). On the other
and, the regression of the plaque occurred after one year of
tatin therapy (simvastatin 40 mg/day) and three years of
tatin therapy (pravastatin 10 mg/day) (29,30). A recent
ingle-center, small study indicated that the decrease of
umen volume without shrinkage of coronary arteries re-
ulted in a significant reduction of plaque volume after six
onths of statin therapy (atorvastatin 20 mg/day) in pa-
ients with acute coronary syndrome (31). Taking an overall
iew of these studies, a significant regression of the plaque
an be seen from six months to three years after statin
herapy. However, previous large-scale, long-term studies,
hich indicated the prognosis of the patients with hyper-
ipidemia, showed improvements in the event-free ratio of
he statin therapy group after only six months (32,33). This
eans that plaque stability is achieved by the change of
laque contents, such as the removal of lipids from the
ipid-rich plaques and an increase in fibrous tissue, despite
nly a minimal morphologic regression of plaque after only
ix months of the statin therapy.
tudy limitations. First, we manually excluded the vessel
umen and the area outside of the coronary artery intima
rom the entire 2D IB IVUS image. To improve the
ccuracy (intraobserver and interobserver variabilities of the
nalysis), computerized assessment of the coronary lumen
nd atherosclerotic plaque dimensions will be required in
he future. Second, the 3D IB IVUS images presented in
his study do not represent a true spatial reconstruction of
laque geometry, but simply a connection of consecutive 18
B IVUS images captured at an interval of 1 mm using
otorized pull-back system. The number of captured im-
ges depends on the storage capacity and processing speed
f the personal computer. Future studies will address these
roblems. Third, calcification is a perfect reflector for
ltrasound, causing the acoustic shadowing so typical in the
VUS images. The RF signals not able to penetrate or pass
hrough the calcified layer are reflected back toward the
ransducer (34). Therefore, an accurate calculation of calci-
ed volume was not possible, although the calculation for
he high RF signal lesion was performed in the present
tudy. Fourth, previous histologic studies showed that IB
easurements accurately reflected the tissue characteristicsf human coronary arterial plaques. However, these com-
1arisons between IB values and histologic categories were
erformed in two-dimensional color-coded maps. A 3D
omparison will be required in the future. Furthermore,
ecause the number of patients in this study was small and
he follow-up period was short, analysis of the incidence of
ascular events was not possible. In addition, six months was
ot enough to detect changes in plaque composition.
arge-scale, long-term studies, which include an analysis of
he incidence of acute coronary syndrome, will be required
n the future.
onclusions. Three-dimensional IB IVUS, which depicts
issue characteristics of plaques, offers an improvement over
onventional IVUS techniques for the tissue characteriza-
ion of plaques and the assessment of the history of coronary
therosclerosis. Statin therapy reduced the lipid component
n patients with stable angina without reducing the degree
f stenosis. Quantitative evaluation using 3D IB IVUS
mages may lead to elucidation of the progression process of
nstable plaques in the clinical settings and prevention of
cute coronary syndrome.
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